Compare OPY & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPY | BHVN |
|---|---|---|
| Founded | 1881 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2022 |
| Metric | OPY | BHVN |
|---|---|---|
| Price | $97.21 | $10.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.08 |
| AVG Volume (30 Days) | 69.6K | ★ 1.6M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 104.71 | 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,638,071,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.13 | ★ N/A |
| Revenue Growth | ★ 14.35 | N/A |
| 52 Week Low | $59.69 | $7.48 |
| 52 Week High | $118.77 | $22.22 |
| Indicator | OPY | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 52.76 |
| Support Level | $82.75 | $9.41 |
| Resistance Level | $118.77 | $10.22 |
| Average True Range (ATR) | 5.31 | 0.66 |
| MACD | -1.82 | -0.03 |
| Stochastic Oscillator | 12.85 | 54.98 |
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.